zurück

Selpercatinib (new indication: thyroid cancer, RET-mutation, monotherapy, patients aged ≥ 12 years)

 

Subject:

  • Active Substance: Selpercatinib
  • Name: Retsevmo®
  • Therapeutic area: Thyroid cancer
  • Pharmaceutical company: Lilly Deutschland GmbH

 

Time table:

  • Start: 01.10.2022
  • Publication of assessment: 02.01.2023
  • End of public hearing: 23.01.2023
  • Final decision by G-BA: middle of March 2023

 

Comparative therapy:

  • Vandetanib or cabozantinib